Review
Immunology
Ines Bernardoff, Alexandre Picq, Pierre Loiseau, Thomas Foret, Virginie Dufrost, Thomas Moulinet, Ozan Unlu, Doruk Erkan, Denis Wahl, Stephane Zuily
Summary: This study conducted a systematic review and meta-analysis to evaluate the association of antiphospholipid antibodies (aPL) with autoimmune hemolytic anemia in systemic lupus erythematosus (SLE) patients. The results showed a strong association between the presence of aPL and the occurrence of hemolytic anemia in SLE patients, with lupus anticoagulant and anti beta 2Glycoprotein I antibodies having the highest risk. IgM isotypes also indicated an increased risk of hemolytic anemia in SLE.
AUTOIMMUNITY REVIEWS
(2022)
Review
Biochemistry & Molecular Biology
Ryo Hisada, Tatsuya Atsumi
Summary: Despite advances in treatment, thrombosis remains the leading cause of death in SLE. aPL are the main triggers of thrombosis in SLE patients, with a frequency of approximately 30-40%. Lupus anticoagulant, anticardiolipin, anti-beta 2-glycoprotein I antibodies, and non-criteria aPL are risk factors for thrombosis in SLE. Multiple positivity for aPL and calculated scores can predict the risk of thrombosis. Treatment with anticoagulants and/or low-dose aspirin may be appropriate for aPL-positive SLE patients.
Article
Rheumatology
George C. Drosos, Daisy Vedder, Eline Houben, Laura Boekel, Fabiola Atzeni, Sara Badreh, Dimitrios T. Boumpas, Nina Brodin, Ian N. Bruce, Miguel Angel Gonzalez-Gay, Soren Jacobsen, Gyorgy Kerekes, Francesca Marchiori, Chetan Mukhtyar, Manuel Ramos-Casals, Naveed Sattar, Karen Schreiber, Savino Sciascia, Elisabet Svenungsson, Zoltan Szekanecz, Anne-Kathrin Tausche, Alan Tyndall, Vokko van Halm, Alexandre Voskuyl, Gary J. Macfarlane, Michael M. Ward, Michael T. Nurmohamed, Maria G. Tektonidou
Summary: This study developed recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, emphasizing the importance of regular screening and management of modifiable CVR factors as well as patient education. The recommendations covered CVR prediction tools, interventions on traditional CVR factors, and interventions on disease-related CVR factors.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Medicine, General & Internal
Nuria Banos, Aleida Castellanos, Giuseppe Barilaro, Francesc Figueras, Gema Lledo, Marta Santana, Gerard Espinosa
Summary: A prospective study was conducted on pregnant women with SLE, antiphospholipid syndrome, or non-criteria obstetric antiphospholipid syndrome to develop a predictive tool for adverse pregnancy outcomes. Baseline characteristics and certain biomarkers were found to be predictive of adverse outcomes, highlighting the need for better biomarkers for pregnant women with autoimmune diseases.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Immunology
Antonio Marinho, Jose Delgado Alves, Jorge Fortuna, Raquel Faria, Isabel Almeida, Gloria Alves, Joao Araujo Correia, Ana Campar, Mariana Brandao, Jorge Crespo, Daniela Marado, Joao Matos-Costa, Susana Oliveira, Fernando Salvador, Lelita Santos, Fatima Silva, Milene Fernandes, Carlos Vasconcelos
Summary: "Evidence and practice-based guidance for off-label use of biologics in SLE, APS, and SS: a comprehensive literature review and expert consensus resulted in 32 final recommendations, considering organ involvement, manifestations, severity, and response to previous treatments."
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Clinical Neurology
Kevin Kyle, Yvette Bordelon, Nagagopal Venna, Jenny Linnoila
Summary: Autoimmune chorea syndromes encompass a wide range of disorders including paraneoplastic, parainfectious, and idiopathic diseases. Familiarity with these disorders is important as they can be treatable or part of a syndrome requiring further investigation and monitoring. These disorders involve abnormal immune attack leading to neuronal dysfunction and chorea, often accompanied by other neurological or systemic manifestations.
FRONTIERS IN NEUROLOGY
(2022)
Article
Biochemistry & Molecular Biology
Tatiana Reshetnyak, Kamila Nurbaeva, Ivan Ptashnik, Anna Kudriaeva, Alexey Belogurov Jr, Aleksandr Lila, Evgeny Nasonov
Summary: This study aimed to assess the role of neutrophil extracellular traps (NETs) markers, MPO-DNA complex and nucleosomes, in the diagnosis of systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). The study found that levels of MPO-DNA complex were higher in SLE patients and associated with SLE activity and lupus glomerulonephritis. Lower levels of nucleosomes were observed in SLE patients and associated with SLE activity and arthritis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Fulvia Ceccarelli, Francesco Natalucci, Giulio Olivieri, Carmelo Pirone, Licia Picciariello, Valeria Orefice, Simona Truglia, Francesca Romana Spinelli, Cristiano Alessandri, Antonio Chistolini, Fabrizio Conti
Summary: We longitudinally followed a cohort of aPL positive healthy subjects and found that nearly 15% of them developed systemic autoimmune diseases (sAD). The presence of triple positivity status was significantly associated with the progression to sAD, suggesting its potential role as a biomarker for this condition. Regular follow-up for these patients is recommended for early diagnosis and treatment.
Review
Biochemistry & Molecular Biology
Wojciech Lubon, Malgorzata Lubon, Przemyslaw Kotyla, Ewa Mrukwa-Kominek
Summary: Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease, with up to one-third of patients experiencing various ocular manifestations. Ocular findings may be the initial signs of the disease and can lead to severe complications and vision loss. Early diagnosis and proper management are crucial, requiring collaboration among specialists. Adequate preparation of ophthalmologists can help differentiate SLE complications from other eye disorders. New therapies for SLE show promise, but their ocular side effects are still unknown.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Tatiana Reshetnyak, Fariza Cheldieva, Maria Cherkasova, Alexander Lila, Evgeny Nasonov
Summary: This study investigates the role of IgA antibodies to cardiolipin (aCL) and IgA antibodies to beta-2 glycoprotein 1 (anti-beta(2)-GP1) in the development of vascular complications in patients with antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE). The results show that the levels of IgA aCL and IgA anti-beta(2)-GP1 are significantly higher in APS patients compared to SLE patients and the control group. These antibodies are closely associated with thrombosis in APS, demonstrating high specificity but low sensitivity for the diagnosis of APS.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Rheumatology
Antonis Fanouriakis, Myrto Kostopoulou, Jeanette Andersen, Martin Aringer, Laurent Arnaud, Sang-Cheol Bae, John Boletis, Ian N. Bruce, Ricard Cervera, Andrea Doria, Thomas Doerner, Richard A. Furie, Dafna D. Gladman, Frederic A. Houssiau, Luis Sousa Ines, David Jayne, Marios Kouloumas, Laszlo Kovacs, Chi Chiu Mok, Eric F. Morand, Gabriella Moroni, Marta Mosca, Johanna Mucke, Chetan B. Mukhtyar, Gyoergy Nagy, Sandra Navarra, Ioannis Parodis, Jose M. Pego-Reigosa, Michelle Petri, Bernardo A. Pons-Estel, Matthias Schneider, Josef S. Smolen, Elisabet Svenungsson, Yoshiya Tanaka, Maria G. Tektonidou, Y. K. Onno Teng, Angela Tincani, Edward M. Vital, Ronald F. van Vollenhoven, Chris Wincup, George Bertsias, Dimitrios T. Boumpas
Summary: The EULAR recommendations for the management of systemic lupus erythematosus (SLE) have been updated based on emerging new evidence. The updated recommendations provide consensus guidance on the use of various medications and treatment strategies to control the disease, as well as recommendations for assessing treatment response and tapering therapy.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Jingru Tian, Dingyao Zhang, Xu Yao, Yaqing Huang, Qianjin Lu
Summary: This study estimated the epidemiology of SLE globally, finding variations in incidence and prevalence rates across different countries and regions. It also highlighted the impact of gender, age, and prevalence estimation method on the findings. SLE was found to occur more frequently in high-income countries.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Immunology
Jessica S. Kleer, Pascal A. Rabatscher, Jessica Weiss, Joel Leonardi, Severin B. Vogt, Andrea Kieninger-Grafitsch, Carlo Chizzolini, Uyen Huynh-Do, Camillo Ribi, Marten Trendelenburg
Summary: The study found that epitope-specific anti-C1q in SLE patients is associated with specific disease manifestations, providing more diagnostic value than conventional anti-C1q.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Mingxuan Chi, Kuai Ma, Yunlong Li, Min Quan, Zhongyu Han, Zhaolun Ding, Xin Liang, Qinxiu Zhang, Linjiang Song, Chi Liu
Summary: Systemic lupus erythematosus (SLE) is a typical autoimmune disease characterized by multiple immunoregulatory abnormalities that lead to damage to various tissues and organs. Researchers have identified aberrant expression of miRNAs in SLE patients, which may be associated with abnormal immune responses and disease progression in SLE.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Immunology
Aleida Susana Castellanos Gutierrez, Francesc Figueras, Diana M. Morales-Prieto, Ekkehard Schleussner, Gerard Espinosa, Nuria Banos
Summary: Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease that mainly affects women of childbearing age. During pregnancy, SLE is associated with a higher risk of perinatal morbidity and mortality. Several studies have suggested that placental dysfunction may play a crucial role in this association.
FRONTIERS IN IMMUNOLOGY
(2022)